Source: The Bulwark
by Brent Orrell
“As holiday treats give way to New Year’s resolutions, the names of GLP-1 weight-loss drugs like Ozempic and Wegovy will be on millions of lips this January — in addition to any leftover fruitcake, eggnog, cookies, and latkes. But the benefits of these drugs aren’t limited to what they can do for an individual’s health. Recent analysis of GLP-1 weight-loss therapies by Citi and Goldman Sachs uncovered an interesting and underdiscussed benefit: increased worker productivity. Widely deployed, these drugs could raise labor productivity by up to 0.5 percent. That number may not sound like much, but such an acceleration would be a dramatic boost to the economy of the United States and the health of its citizens.” (01/07/25)
https://www.thebulwark.com/p/ozempic-community-glp-1-wegovy-weight-loss-obesity-workforce